Literature DB >> 25286251

(99m)Tc-3P-RGD2 micro-single-photon emission computed tomography/computed tomography provides a rational basis for integrin αvβ3-targeted therapy.

Tong Fu1, Wei Qu, Fan Qiu, Yan Li, Guoqiang Shao, Wei Tian, Zichun Hua, Yingjian Zhang, Feng Wang.   

Abstract

PURPOSE: This study was to demonstrate the utility of (99m)Tc-3P-RGD2 micro-single-photon emission computed tomography/computed tomography (SPECT/CT) for the integrin αvβ3 expression quantification in NCI-H446 and A549 lung cancer xenografts.
MATERIALS AND METHODS: (99m)Tc-3P-RGD2 was prepared with high radiochemical purity (97%±2%) and showing high in vitro stability. The in vitro affinities of (99m)Tc-3P-RGD2 to NCI-H446 and A549 tumor cells were analyzed with γ-counter, while the in vivo uptakes in NCI-H446 and A549 xenografts were evaluated with micro-SPECT/CT. The region of interest was drawn over the tumor site and contralateral muscle on the SPECT/CT image, and the tumor to nontumor (T/NT) ratio was calculated to estimate αvβ3 expression and tumor uptake. The expressions of integrin αvβ3 in vitro and in vivo were analyzed using a flow cytometer and immunofluorescence.
RESULTS: Micro-SPECT/CT demonstrated focal uptake in the tumors. T/NT ratio in NCI-H446 xenografts was significantly higher compared with the A549 tumor model, as 5.92±0.82 and 3.62±0.91, respectively, with p<0.05. In addition, integrin αvβ3 expression in NCI-H446 cells was significantly higher compared with the A549 cells, which was consistent with the imaging data. A linear relationship was observed between (99m)Tc-3P-RGD2 uptake and αvβ3 expression (R(2)=0.7667, p<0.001).
CONCLUSION: (99m)Tc-3P-RGD2 SPECT/CT could be used to quantify integrin αvβ3 expression within tumors, providing a rational basis for integrin αvβ3-targeted cancer therapy.

Entities:  

Keywords:  99mTc-3P-RGD2; NSCLC; anti-angiogenesis; integrin αvβ3; quantification

Mesh:

Substances:

Year:  2014        PMID: 25286251      PMCID: PMC4224041          DOI: 10.1089/cbr.2014.1622

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  27 in total

1.  Evaluation of 99mTc-labeled cyclic RGD dimers: impact of cyclic RGD peptides and 99mTc chelates on biological properties.

Authors:  Yang Zhou; Young-Seung Kim; Xin Lu; Shuang Liu
Journal:  Bioconjug Chem       Date:  2012-03-06       Impact factor: 4.774

2.  (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.

Authors:  Zhaofei Liu; Yongjun Yan; Shuanglong Liu; Fan Wang; Xiaoyuan Chen
Journal:  Bioconjug Chem       Date:  2009-05-20       Impact factor: 4.774

Review 3.  Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging.

Authors:  Shuang Liu
Journal:  Mol Pharm       Date:  2006 Sep-Oct       Impact factor: 4.939

4.  Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer 99mTc-3PRGD 2 in non-human primates.

Authors:  Bing Jia; Zhaofei Liu; Zhaohui Zhu; Jiyun Shi; Xiaona Jin; Huiyun Zhao; Fang Li; Shuang Liu; Fan Wang
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

5.  [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.

Authors:  Clemens Decristoforo; Bluma Faintuch-Linkowski; Ana Rey; Elisabeth von Guggenberg; Marco Rupprich; Ignacio Hernandez-Gonzales; Teodoro Rodrigo; Roland Haubner
Journal:  Nucl Med Biol       Date:  2006-11       Impact factor: 2.408

6.  Antiangiogenic gene therapy of experimental pancreatic tumor by sFlt-1 plasmid DNA carried by RGD-modified crosslinked polyplex micelles.

Authors:  Yelena Vachutinsky; Makoto Oba; Kanjiro Miyata; Shigehiro Hiki; Mitsunobu R Kano; Nobuhiro Nishiyama; Hiroyuki Koyama; Kohei Miyazono; Kazunori Kataoka
Journal:  J Control Release       Date:  2010-02-06       Impact factor: 9.776

7.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

8.  Integrin targeted delivery of chemotherapeutics.

Authors:  Kai Chen; Xiaoyuan Chen
Journal:  Theranostics       Date:  2011-02-17       Impact factor: 11.556

Review 9.  Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.

Authors:  Susanna V Ulahannan; Julie R Brahmer
Journal:  Cancer Invest       Date:  2011-05       Impact factor: 2.176

10.  Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit.

Authors:  Gaetano Santulli; Maria Felicia Basilicata; Mariarosaria De Simone; Carmine Del Giudice; Antonio Anastasio; Daniela Sorriento; Michele Saviano; Annarita Del Gatto; Bruno Trimarco; Carlo Pedone; Laura Zaccaro; Guido Iaccarino
Journal:  J Transl Med       Date:  2011-01-13       Impact factor: 5.531

View more
  2 in total

1.  [99mTc]Tc-Galacto-RGD2 integrin αvβ3-targeted imaging as a surrogate for molecular phenotyping in lung cancer: real-world data.

Authors:  Jingjing Fu; Yan Xie; Tong Fu; Fan Qiu; Fei Yu; Wei Qu; Xiaochen Yao; Aiping Zhang; Zhenhua Yang; Guoqiang Shao; Qingle Meng; Xiumin Shi; Yue Huang; Wei Gu; Feng Wang
Journal:  EJNMMI Res       Date:  2021-06-13       Impact factor: 3.138

2.  99mTc-3PRGD2 single-photon emission computed tomography/computed tomography for the diagnosis of choroidal melanoma: A preliminary STROBE-compliant observational study.

Authors:  Bing Yan; Tong Fu; Yueming Liu; Wenbin Wei; Haojie Dai; Wei Fang; Feng Wang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.